Endo, Inc. operates as a diversified specialty pharmaceutical company.
The company develops, manufactures, markets and sells a broad portfolio of pharmaceutical products across four reportable segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals.
A significant portion of the company's sales, including sales to hospitals, clinics and long-term care facilities in the United States, are controlled by a relatively small number of GPOs, i...
Endo, Inc. operates as a diversified specialty pharmaceutical company.
The company develops, manufactures, markets and sells a broad portfolio of pharmaceutical products across four reportable segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals.
A significant portion of the company's sales, including sales to hospitals, clinics and long-term care facilities in the United States, are controlled by a relatively small number of GPOs, including HealthTrust Purchasing Group, L.P., Premier Inc. and Vizient, Inc.
Business Strategy
The company's strategy is driven by its aspiration to be a vibrant, growing, diversified specialty pharmaceutical company delivering innovative, life-enhancing products. The company has three strategic priorities which are intended to guide all that the company does to achieve this aspiration and drive long-term value for the company's stakeholders.
The company's first strategic priority is to Expand and Enhance the company's Portfolio. For the company's Branded Pharmaceuticals segment, this includes driving sustained long-term growth in XIAFLEX through focused investment, successfully leveraging the XIAFLEX pipeline-in-a-product platform to pursue new indications that will provide a more fulsome suite of non-surgical solutions to treat 'hand to foot' conditions, and targeting external opportunities in urology and orthopedics (and potentially adjacent areas) that can leverage existing commercial capabilities to accelerate growth. For the company's Sterile Injectables segment, this includes growing the pipeline through the addition of differentiated and durable product opportunities and successfully launching new products that address the company's customers' needs. For the company's Generic Pharmaceuticals and International Pharmaceuticals segments, this includes limited targeted and opportunistic investments.
The company's second strategic priority is to continue to Reinvent How The company Works. Over the last several years, the company has expanded and modernized the company's internal Sterile Injectable manufacturing capabilities, rationalized the company's Generic Pharmaceutical manufacturing network and transformed the company's general and administrative functions.
The company's third strategic priority centers around the company's commitment to being a Force for Good. This includes promoting values that are consistent with a culture that is able to maintain a highly engaged, inclusive and high-performing team. The company actively manages and monitors team member retention, equity and inclusion initiatives and employee engagement scores. The company also continues to embrace and adopt sustainable practices that seek to promote the safe, efficient and responsible use of global resources, both directly and through the company's suppliers and logistics partners, to minimize impact to the environment. The company actively manages and monitors its water and energy consumption, including Scope 1 and Scope 2 emissions, and waste generation.
Products Overview
Branded Pharmaceuticals
The company's Branded Pharmaceuticals segment focuses on products that have inherent scientific, regulatory, legal and/or technical complexities and are marketed under recognizable brand names that are trademarked. The company's Branded Pharmaceuticals segment includes a variety of branded products across two product portfolios: Specialty Products and Established Products.
The Specialty Products portfolio represents a core area of growth and includes products for the treatment of conditions in urology, orthopedics and endocrinology.
XIAFLEX is an enzyme-based, durable pipeline-in-a-product platform opportunity for Endo. XIAFLEX is the only non-surgical treatment for Peyronie's Disease (for adult men with a collagen plaque and a penile curvature deformity) and Dupuytren's Contracture (for adult patients with an abnormal buildup of collagen in the fingers that limits or disables hand function). Several additional indications for XIAFLEX are in clinical development, including plantar fibromatosis and plantar fasciitis, while others are in pre-clinical development, including arthrofibrosis of the knee following knee arthroplasty.
XIAFLEX is protected by a durable patent estate with patents not limited by indication through the mid-2030s and method of use patents on future indications expected to extend through the late 2030s/early 2040s and potentially beyond. In addition to the durability of the company's patents, competitor development of a non-recombinant biosimilar utilizing the company's cell line is highly unlikely as access to the cell line is physically restricted (in a locked vault). Further, competitor development of a recombinant-biosimilar requires extensive investment and time. The company is not aware of any approved or filed enzyme-based biosimilar products in the United States.
The Established Products portfolio includes six products across diverse areas that are not actively promoted by sales professionals or through advertising and require minimal commercial investment.
Sterile Injectables
The company's Sterile Injectables segment includes a broad portfolio of approximately 40 critical care, maternal health, anesthesia and other products which are administered at hospitals, clinics and long-term care facilities. While most of these products are available as single or multi-dose vials (from which the drug product must be extracted), a growing number of products are or will be available as a ready-to-use bottle, bag or pre-filled syringe, among other presentations.
The company's two largest Sterile Injectable products are ADRENALIN, a non-selective alpha- and beta-adrenergic agonist indicated for emergency treatment of certain allergic reactions, including anaphylaxis, and VASOSTRICT, a product indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
ADRENALIN is only available in a vial. VASOSTRICT is available in both a vial and a ready-to-use bottle. While revenue from the VASOSTRICT vial has declined significantly over the past two years due to availability of competing products, the company has seen approximately 25% of the market convert to the company's VASOSTRICT ready-to-use bottle.
In addition to the diverse portfolio of on-market products, the company has a robust and growing pipeline of nearly 50 mostly ready-to-use and differentiated products addressing operational constraints, such as long preparation time, or risks of errors in dosing, among others, as well as drug cost, safety, shortages and wastage in the hospital setting. Subject to regulatory approval, the company plans to launch 45 of these products over the next five years. These ready-to-use and differentiated products are inherently more challenging to develop and manufacture. As a result, unlike traditional vials, the company's ready-to-use and differentiated products are less easily commoditized, and are generally expected to result in more durable revenue and cash flows.
Generic Pharmaceuticals
The company's Generic Pharmaceuticals segment includes a portfolio of approximately 85 generic product families, including solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, patches, powders, ophthalmics and sprays, and includes products that treat and manage a wide variety of medical conditions. The company's generic portfolio also contains certain authorized generics, which are generic versions of branded products licensed by brand drug companies and marketed as generics, including, among others, lidocaine patch 5% (the authorized generic of Lidoderm), lubiprostone capsules (the authorized generic of Mallinckrodt Pharmaceuticals' Amitiza) and sucralfate oral suspension 1 gm/10 ml (the authorized generic of AbbVie Inc.'s Carafate). While the company plans to continue to invest in targeted product development opportunities and has several products in the company's pipeline that are expected to launch over the next several years, the Generic Pharmaceutical segment is not considered a growth area.
International Pharmaceuticals
The company's International Pharmaceuticals segment sells a variety of specialty pharmaceutical products outside the United States, primarily to customers in Canada through the company's wholly owned subsidiary in Canada. The key products of this segment serve various therapeutic areas, including attention deficit hyperactivity disorder, pain, women's health, oncology and transplantation, as well as over-the-counter products. While the company plans to continue to invest in targeted new product opportunities through external business development and expect solid growth for several recently launched products, the International Pharmaceutical segment is not considered a core growth area for the company due to its relatively small size.
Select Development Projects
XIAFLEX
XIAFLEX is approved by the FDA and marketed in the United States for the treatment of both Dupuytren's Contracture and Peyronie's Disease (two separate indications). In early 2020, the company had initiated its XIAFLEX development program for the treatment of plantar fibromatosis. In March 2023, the company announced top-line results from the company's Phase 2 clinical study of XIAFLEX in participants with plantar fibromatosis and while the primary endpoint, improvement from baseline in the FFI Pain subscale score when compared to those receiving placebo, when analyzed with the overall study population did not meet statistical significance, a large patient sub-population (72% of the overall study population) showed statistically significant improvement across a majority of endpoints, including but not limited to the FFI Pain subscale, the investigator assessment of improvement (Clinician Global Impression of Change), nodule hardness and improvement in nodule consistency. The CCH safety profile in the Phase 2 clinical study was consistent with the known CCH safety profile from other studies. Most adverse events were rated as mild to moderate and there were no treatment-related serious adverse events. The company initiated the Phase 3 clinical program in the fourth quarter of 2023. The company also completed a proof-of-concept study in plantar fasciitis during the third quarter of 2023 and, based on encouraging proof-of-concept study results, initiated the Phase 2 clinical study in the fourth quarter of 2023. The company may in the future develop the company's XIAFLEX product for potential additional indications, advancing the company's strategy of developing both non-surgical orthopedic and non-orthopedic care interventions.
Other
The company's remaining pipeline mainly consists of a variety of product candidates in the company's Sterile Injectables and Generic Pharmaceuticals segments. As of March 31, 2024, within these two segments, the company was actively pursuing approximately 63 product candidates, including: (i) approximately 15 ANDAs pending with the FDA, of which approximately 53% are associated with the company's Sterile Injectables segment, as well as (ii) approximately 48 additional projects in development, of which approximately 92% are associated with the company's Sterile Injectables segment, including RTU and other more differentiated product candidates.
The company expects to continue to focus investments in RTU and other differentiated product candidates in the company's Sterile Injectables segment, potentially including acquisitions and/or license and commercialization agreements.
The company's primary approach to developing generic products for these two segments is to target high-barrier-to-entry product opportunities, including first-to-file or first-to-market opportunities that are difficult to formulate or manufacture or face complex legal and regulatory challenges as well as products that meet the evolving needs of hospitals and health systems. The company expects such product opportunities to result in products that are either the exclusive generic or have two or fewer generic competitors when launched, which tends to lead to more sustainable market share and profitability for the company's product portfolio. In the company's Sterile Injectables segment, the company also focuses on developing injectable products with inherent scientific, regulatory, legal and/or technical complexities, as well as developing other dosage forms and technologies.
Major Customers
The company primarily sells its products to wholesalers, retail drug store chains, supermarket chains, mass merchandisers, distributors, mail order accounts, hospitals and/or government agencies. The company's wholesalers and/or distributors purchase products from the company and, in turn, supply products to retail drug store chains, independent pharmacies, hospitals, long-term care facilities, clinics, home infusion pharmacies, government facilities and managed care organizations, also referred to as MCOs.
Net revenues from direct customers that accounted for 10% or more of the company's total consolidated net revenues during the year ended December 31, 2023, are as follows: Cencora, Inc., previously known as AmerisourceBergen Corporation; McKesson Corporation; Cardinal Health, Inc.; and CVS Health Corporation (during the second quarter of 2022, CVS Health Corporation finalized the acquisition of US Bioservices Corporation from Cencora, Inc. (known as AmerisourceBergen Corporation at the time)). Net revenues from these customers generally are included within each of the company's segments. XIAFLEX sales account for a significant portion of the company's total revenues and a significant portion of net revenues from certain of these customers.
Some wholesalers and distributors have required pharmaceutical manufacturers, including the company, to enter into distribution service agreements pursuant to which the wholesalers and distributors provide pharmaceutical manufacturers with certain services as well as certain information including, without limitation, periodic retail demand information, current inventory levels and other information. The company has entered into certain of these agreements.
Competition
Branded Pharmaceuticals
This segment's major competitors are Viatris Inc., or Viatris; Jazz Pharmaceuticals plc, or Jazz; Takeda Pharmaceutical Company Limited; and Amgen, Inc., among others.
Sterile Injectables
This segment's major competitors are Pfizer Hospital US, Fresenius Kabi USA, LLC, Viatris, Amphastar Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc., or Amneal, Hikma Pharmaceuticals PLC, Sandoz Group AG (Sandoz) and Eagle Pharmaceuticals, Inc., or Eagle, among others.
Generic Products
The company's major competitors are Teva Pharmaceutical Industries Limited, Viatris, Sandoz, Aurobindo Pharma Limited and Amneal, among others.
Patents, Trademarks, Licenses and Proprietary Property
As of June 4, 2024, the company held approximately: 137 U.S. issued patents, 37 U.S. patent applications pending, 374 foreign issued patents and 127 foreign patent applications pending. In addition, as of June 4, 2024, the company had licenses for approximately 60 U.S. issued patents, 15 U.S. patent applications pending, 130 foreign issued patents and 65 foreign patent applications pending. The company is seeking additional patent protection for several products, including XIAFLEX.
The company's products are subject to different patent expiration dates. For example, the company's patents related to NASCOBAL Nasal Spray expire in 2024, the company's patents related to AVEED expire in 2027 and the company's patents related to ADRENALIN expire in 2035.
While the company considers its overall patent portfolio to be important to the operation of the company's business, except for the company's U.S. patents related to XIAFLEX, no other single patent or patent portfolio is material to the company's business as a whole. XIAFLEX is a biological product. The company owns or has licensed rights to patents and patent applications related to XIAFLEX, including drug product and methods of manufacture patents and patent applications that will expire into the late 2030s and methods of use patent applications for uses such as plantar fibromatosis that are expected to expire into the late 2030s/early 2040s and potentially beyond. The company is not aware of any material contested proceedings or third-party claims related to the company's XIAFLEX patents.
Governmental Regulation
Certain of the company's products are regulated and marketed as biologic products pursuant to BLAs. The company's BLA-licensed products were licensed based on a determination by the FDA of safety, purity and potency as required under the U.S. Public Health Service Act of 1944, as amended, or the PHSA.
Certain of the company's subsidiaries sell products that are 'controlled substances' as defined in the CSA and implementing regulations, which establish certain security and recordkeeping requirements administered by the DEA. The DEA regulates chemical compounds as Schedule I, II, III, IV or V substances, with Schedule I substances considered to present the highest risk of substance abuse and Schedule V substances the lowest risk. The active ingredients in some of the company's products are listed by the DEA as Schedule II or III substances under the CSA. Consequently, their manufacture, shipment, storage, sale and use are subject to a high degree of regulation.
The DEA limits the availability of the active ingredients that are subject to the CSA used in several of the company's products, as well as the production of these products. The company or its contract manufacturing organizations must annually apply to the DEA for procurement and production quotas in order to obtain and produce these substances.
Research and Development (R&D)
The company's total R&D expenses were $115.5 million in 2023, of which $54.9 million related to its Branded Pharmaceuticals development projects.
History
Endo, Inc. was founded in 1997. The company was incorporated in 2013.
